Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.
Johnson DB, Childress MA, Chalmers ZR, Frampton GM, Ali SM, Rubinstein SM, Fabrizio D, Ross JS, Balasubramanian S, Miller VA, Stephens PJ, Sosman JA, Lovly CM. Johnson DB, et al. Among authors: fabrizio d. Pigment Cell Melanoma Res. 2018 May;31(3):432-436. doi: 10.1111/pcmr.12674. Epub 2017 Dec 16. Pigment Cell Melanoma Res. 2018. PMID: 29171936 Free PMC article.
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM. Johnson DB, et al. Among authors: fabrizio d. Cancer Immunol Res. 2016 Nov;4(11):959-967. doi: 10.1158/2326-6066.CIR-16-0143. Epub 2016 Sep 26. Cancer Immunol Res. 2016. PMID: 27671167 Free PMC article.
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, Lieber DS, Roels S, White J, Otto GA, Ross JS, Garraway L, Miller VA, Stephens PJ, Frampton GM. Chalmers ZR, et al. Among authors: fabrizio d. Genome Med. 2017 Apr 19;9(1):34. doi: 10.1186/s13073-017-0424-2. Genome Med. 2017. PMID: 28420421 Free PMC article.
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.
Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. Subbiah V, et al. Among authors: fabrizio d. JCI Insight. 2017 Apr 20;2(8):e90380. doi: 10.1172/jci.insight.90380. eCollection 2017 Apr 20. JCI Insight. 2017. PMID: 28422758 Free PMC article.
Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma.
Dagogo-Jack I, Fabrizio D, Lennerz J, Schrock AB, Young L, Mino-Kenudson M, Digumarthy SR, Heist RS, Ali SM, Miller VA, Shaw AT. Dagogo-Jack I, et al. Among authors: fabrizio d. J Thorac Oncol. 2017 Oct;12(10):e155-e157. doi: 10.1016/j.jtho.2017.04.023. Epub 2017 May 9. J Thorac Oncol. 2017. PMID: 28499860 Free PMC article. No abstract available.
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, Daniel S, Covert M, Frampton GM, Hsu S, Lesser GJ, Stogner-Underwood K, Mott RT, Rush SZ, Stanke JJ, Dahiya S, Sun J, Reddy P, Chalmers ZR, Erlich R, Chudnovsky Y, Fabrizio D, Schrock AB, Ali S, Miller V, Stephens PJ, Ross J, Crawford JR, Ramkissoon SH. Johnson A, et al. Among authors: fabrizio d. Oncologist. 2017 Dec;22(12):1478-1490. doi: 10.1634/theoncologist.2017-0242. Epub 2017 Sep 14. Oncologist. 2017. PMID: 28912153 Free PMC article.
Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.
Ross JS, Gay LM, Wang K, Vergilio JA, Suh J, Ramkissoon S, Somerset H, Johnson JM, Russell J, Ali S, Schrock AB, Fabrizio D, Frampton G, Miller V, Stephens PJ, Elvin JA, Bowles DW. Ross JS, et al. Among authors: fabrizio d. Ann Oncol. 2017 Oct 1;28(10):2539-2546. doi: 10.1093/annonc/mdx399. Ann Oncol. 2017. PMID: 28961851 Free PMC article.
General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
Lee H, El Jabbour T, Ainechi S, Gay LM, Elvin JA, Vergilio JA, Suh J, Ramkissoon SH, Ali SM, Schrock A, Fabrizio D, Frampton G, Nazeer T, Miller VA, Stephens PJ, Ross JS. Lee H, et al. Among authors: fabrizio d. Hum Pathol. 2017 Dec;70:84-91. doi: 10.1016/j.humpath.2017.10.007. Epub 2017 Oct 24. Hum Pathol. 2017. PMID: 29079173
ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.
Ross JS, Ali SM, Fasan O, Block J, Pal S, Elvin JA, Schrock AB, Suh J, Nozad S, Kim S, Jeong Lee H, Sheehan CE, Jones DM, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Miller VA, Stephens PJ, Gay LM. Ross JS, et al. Among authors: fabrizio d. Oncologist. 2017 Dec;22(12):1444-1450. doi: 10.1634/theoncologist.2016-0488. Epub 2017 Oct 27. Oncologist. 2017. PMID: 29079636 Free PMC article.
81 results